Abcam has announced a research collaboration with the Loulou Foundation to discover new tools to advance research for the development of therapeutics for CDKL5 Deficiency Disorder.
The collaboration intends to discover new tools to advance research in this area of high unmet medical need, as the Loulou Foundation will work closely with Abcam’s team of antibody development experts using its proprietary RabMAb technology to generate novel rabbit monoclonal antibody reagents for detection of CDKL5.
The project has the potential to significantly enhance and accelerate research into CDKL5 Deficiency Disorder via development of new, more relevant high-throughput assays.
Daniel Lavery, chief scientific officer at the Loulou Foundation, commented: “Despite ongoing research, the mechanisms responsible for the neurodevelopmental delay and epilepsy caused by CDKL5 Deficiency Disorder remain unknown.”
CDKL5 Deficiency Disorder is among the most prevalent monogenic neurodevelopmental and epileptic disorders, with an incidence rate of approximately 1 in 40,000 live births.
He continued, “The lack of quality reagents for detecting the expression and function of CDKL5 has been a significant hurdle to our understanding of the biology. We are excited to be partnering with Abcam on this critical project to identify and develop the vital tools to drive research into this devastating disorder.”
Current anti-epileptic treatments are only partially effective for the CDKL5 Deficiency Disorder and there is no treatment for the neurodevelopmental delay.
